In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Macrogenics Inc (NASDAQ: MGNX) closed at $15.41 down -1.28% from its previous closing price of $15.61. In other words, the price has decreased by $-1.28 from its previous closing price. On the day, 0.77 million shares were traded. MGNX stock price reached its highest trading level at $15.765 during the session, while it also had its lowest trading level at $14.94.
Ratios:
For a deeper understanding of Macrogenics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On March 04, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $12 to $24.
H.C. Wainwright Downgraded its Buy to Neutral on February 14, 2024, whereas the target price for the stock was revised from $12 to $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 04 ’24 when Peters Jeffrey Stuart sold 51,395 shares for $15.55 per share. The transaction valued at 799,148 led to the insider holds 0 shares of the business.
Peters Jeffrey Stuart sold 19,625 shares of MGNX for $421,938 on Mar 06 ’24. The Senior VP and General Counsel now owns 8,895 shares after completing the transaction at $21.50 per share. On Mar 04 ’24, another insider, Risser Eric Blasius, who serves as the Chief Operating Officer of the company, sold 41,159 shares for $19.76 each. As a result, the insider received 813,501 and left with 38,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 964057280 and an Enterprise Value of 778729728. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.41 while its Price-to-Book (P/B) ratio in mrq is 6.27. Its current Enterprise Value per Revenue stands at 13.255 whereas that against EBITDA is -4.91.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.88, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is -9.16%, while the 200-Day Moving Average is calculated to be 61.39%.
Shares Statistics:
For the past three months, MGNX has traded an average of 1.57M shares per day and 974210 over the past ten days. A total of 62.07M shares are outstanding, with a floating share count of 58.71M. Insiders hold about 6.15% of the company’s shares, while institutions hold 94.70% stake in the company. Shares short for MGNX as of 1711584000 were 6446695 with a Short Ratio of 4.10, compared to 1709164800 on 5019240. Therefore, it implies a Short% of Shares Outstanding of 6446695 and a Short% of Float of 12.65.
Earnings Estimates
The stock of Macrogenics Inc (MGNX) is currently drawing attention from REGENXBIO Inc. analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $8.69, with high estimates of $15.41 and low estimates of $39.17.
